Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

September 30, 2008

Study Completion Date

July 31, 2009

Conditions
Sarcoma
Interventions
DRUG

irinotecan hydrochloride

Trial Locations (21)

12

Our Lady's Hospital for Sick Children Crumlin, Dublin

B4 6NH

Birmingham Children's Hospital, Birmingham

BS2 8AE

Institute of Child Health at University of Bristol, Bristol

CB2 2QQ

Addenbrooke's Hospital, Cambridge

LS9 7TF

Leeds Cancer Centre at St. James's University Hospital, Leeds

LE1 5WW

Leicester Royal Infirmary, Leicester

L12 2AP

Royal Liverpool Children's Hospital, Alder Hey, Liverpool

E1 1BB

Royal London Hospital, London

WC1N 3JH

Great Ormond Street Hospital for Children, London

M27 4HA

Royal Manchester Children's Hospital, Manchester

NE1 4LP

Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle upon Tyne

NG7 2UH

Queen's Medical Centre, Nottingham

0X3 9DU

Oxford Radcliffe Hospital, Oxford

S10 2TH

Children's Hospital - Sheffield, Sheffield

SO16 6YD

Southampton General Hospital, Southampton

SM2 5PT

Royal Marsden - Surrey, Sutton

BT12 6BE

Royal Belfast Hospital for Sick Children, Belfast

AB25 2ZG

Royal Aberdeen Children's Hospital, Aberdeen

EH9 1LF

Royal Hospital for Sick Children, Edinburgh

G3 8SJ

Royal Hospital for Sick Children, Glasgow

CF14 4XW

Childrens Hospital for Wales, Cardiff

All Listed Sponsors
lead

Children's Cancer and Leukaemia Group

OTHER

NCT00276692 - Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma | Biotech Hunter | Biotech Hunter